No beneficial effects of amantadine in treatment of chronic hepatitis C patients
| العنوان: | No beneficial effects of amantadine in treatment of chronic hepatitis C patients |
|---|---|
| المؤلفون: | Peter Houben, Nancy A.M. Van Ooteghem, J.M. Vrolijk, Peter D. Siersema, Bart van Hoek, Rob J. Lieverse, Karel J. van Erpecum, Hanneke van Soest, Ger H. Koek, Greet J. Boland, Marguerite E.I. Schipper, Richard A. de Vries, Peter J. van der Schaar, Joost P.H. Drenth, Annet van der Sluys Veer |
| المساهمون: | Interne Geneeskunde, RS: NUTRIM - R2 - Gut-liver homeostasis |
| المصدر: | Digestive and Liver Disease, 42, 7, pp. 496-502 Digestive and Liver Disease, 42, 496-502 Digestive and Liver Disease, 42(7), 496-502 Digestive and Liver Disease, 42(7), 496-502. Elsevier Science |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Genotype, Hepatitis C virus, Hepacivirus, Interferon alpha-2, medicine.disease_cause, Placebo, Antiviral Agents, Gastroenterology, Drug Administration Schedule, Polyethylene Glycols, chemistry.chemical_compound, Internal medicine, Ribavirin, Amantadine, medicine, Humans, Molecular gastro-enterology and hepatology [IGMD 2], Amantadine Hepatitis C PEG-interferon Ribavirin placebo-controlled trial treatment-naive patients alpha-2a plus ribavirin initial treatment virus-infection randomized trial triple therapy double-blind influenza-a interferon, Interferon alfa, Hepatology, biology, business.industry, Interferon-alpha, Hepatitis C, Hepatitis C, Chronic, Middle Aged, Viral Load, medicine.disease, biology.organism_classification, Recombinant Proteins, Intention to Treat Analysis, Surgery, chemistry, Drug Therapy, Combination, Female, business, Viral load, medicine.drug |
| الوصف: | Contains fulltext : 89730.pdf (Publisher’s version ) (Closed access) BACKGROUND: Benefit of adding amantadine to antiviral therapy for hepatitis C is controversial. AIMS: We aimed to examine whether such policy enhances sustained viral response in treatment-naive patients. METHODS: 297 naive hepatitis C patients were randomized for treatment with amantadine 200mg or placebo, combined with weight-based ribavirin and 12-day high-dose interferon alpha-2b induction therapy, followed by PEG-interferon alpha-2b (1.5 microg/kg/week up to 26 weeks and thereafter, 1.0 microg/kg/week until week 52). Treatment was discontinued if hepatitis C virus (HCV) RNA was positive at week 24. RESULTS: 49% of patients were (former) drug users. Genotype 1 occurred in 45%, high viral load in 70% and severe fibrosis/cirrhosis in 32%, without differences between amantadine or placebo groups. 90 patients prematurely discontinued treatment, mainly because of grade 3 or 4 toxicity. Intention-to-treat analysis revealed sustained viral response in 47% and 51% of amantadine and placebo groups (p=0.49). Amantadine did not enhance sustained viral response in patients with genotype 1 or high viral load nor did it improve primary non-response, breakthrough or relapse rates. Genotype non-1 and lower pre-treatment gamma GT levels were independent predictors for sustained viral response. CONCLUSION: Adding amantadine to antiviral therapy of previously untreated chronic hepatitis C patients has no beneficial effects. 01 juli 2010 |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1590-8658 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dde32cd623e5b2aadcd5f1b6414e3213 https://hdl.handle.net/1887/100153 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....dde32cd623e5b2aadcd5f1b6414e3213 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15908658 |
|---|